pacritinib (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Myelofibrosis

Pending FDA approval for myelofibrosis in patients with severe thrombocytopenia (platelet counts <50,000/mm3)

Next:

Pharmacology

Mechanism of Action

Tyrosine kinase inhibitor (TKI); inhibits 4 mutations of the JAK signal transduction pathways (ie, JAK2, FLT3, IRAK1 and CSF1R); mutations in these kinases have been shown to be related to a the development of a variety of blood-related cancers, including myelofibrosis

The JAK family of enzymes is critical for normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.